• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Quartel Adrian W claimed ownership of 2,923 shares (SEC Form 3)

    3/27/25 8:30:21 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZVRA alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Quartel Adrian W

    (Last) (First) (Middle)
    C/O ZEVRA THERAPEUTICS, INC.
    1180 CELEBRATION BOULEVARD, SUITE 103

    (Street)
    CELEBRATION FL 34747

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    12/06/2024
    3. Issuer Name and Ticker or Trading Symbol
    ZEVRA THERAPEUTICS, INC. [ ZVRA ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Medical Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock 2,923(1) D
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) (2) 01/02/2034 Common Stock 300,000 $6.42 D
    Explanation of Responses:
    1. Includes shares held in the Issuer's Employee Stock Purchase Plan (the "ESPP"). Total reflects the purchase of 2,923 ESPP shares.
    2. Grant to the Reporting Person of a stock option under the Issuer's 2023 Employment Inducement Award Plan. The option will vest and become exercisable in four equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant.
    Remarks:
    Exhibit List: Exhibit 24 - Power of Attorney
    /s/ Timothy J. Sangiovanni, Attorney-in-Fact for Adrian W. Quartel 03/27/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ZVRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZVRA

    DatePrice TargetRatingAnalyst
    7/2/2025$26.00Buy
    H.C. Wainwright
    1/8/2025$25.00Overweight
    Cantor Fitzgerald
    10/7/2024$20.00Buy
    Guggenheim
    9/24/2024$17.00Mkt Outperform
    JMP Securities
    9/24/2024$18.00 → $25.00Buy
    Maxim Group
    4/2/2024$12.00 → $18.00Buy
    Maxim Group
    3/12/2024Outperform
    William Blair
    3/17/2023$12.00Buy
    Maxim Group
    More analyst ratings

    $ZVRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

    Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC GeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a new genetic testing program with Zevra Therapeutics, Inc. (NASDAQ:ZVRA), a commercial-stage biopharmaceutical company focused on bringing life-changing therapeutics to people living with rare diseases. The Niemann-Pick Disease type C (NPC) Sponsored Genetic Testing Program is designed to expand access to GeneDx's industry-leading ExomeDx™ test for patients with suspected Niemann-Pick disease type C, helping clinicians reach accurate diag

    3/10/26 8:30:00 AM ET
    $WGS
    $ZVRA
    Retail: Computer Software & Peripheral Equipment
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zevra Reports Fourth Quarter and Full Year 2025 Financial Results

    Q4 net revenue of $34.1 million, representing 31% growth quarter-over-quarter FY 2025 net revenue of $106.5 million, driven by growth in MIPLYFFA® net revenue to $87.4 million 2025 EPS of $1.40 basic and $1.35 diluted  Company to host conference call and webcast TODAY, March 9, 2026, at 4:30 p.m. ET BOSTON, March 09, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today reported its financial results for the fourth quarter and full year ended December 31, 2025. "MIPLYFFA is making a meaningful difference for patients with Niemann-Pick disease type C, a

    3/9/26 4:05:00 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zevra Therapeutics Appoints Justin Renz as Chief Financial Officer

    CELEBRATION, Fla., March 05, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the appointment of Justin Renz as Chief Financial Officer, effective March 9, 2026. Mr. Renz brings more than 25 years of financial leadership experience in the biopharmaceutical industry, including extensive expertise in capital markets, strategic transactions, and commercial-stage operations. "Justin is a highly accomplished financial executive with a strong track record of driving growth and creating shareholder value across multiple biopharmaceutical organizat

    3/5/26 7:30:00 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Zevra Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Zevra Therapeutics with a rating of Buy and set a new price target of $26.00

    7/2/25 7:59:19 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald resumed coverage on Zevra Therapeutics with a new price target

    Cantor Fitzgerald resumed coverage of Zevra Therapeutics with a rating of Overweight and set a new price target of $25.00

    1/8/25 8:49:26 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Zevra Therapeutics with a new price target

    Guggenheim initiated coverage of Zevra Therapeutics with a rating of Buy and set a new price target of $20.00

    10/7/24 8:28:23 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVRA
    SEC Filings

    View All

    $ZVRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form S-8 filed by Zevra Therapeutics Inc.

    S-8 - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

    3/9/26 4:27:34 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Zevra Therapeutics Inc.

    10-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

    3/9/26 4:23:20 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zevra Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

    8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

    3/9/26 4:06:10 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Mcfarlane Neil F. converted options into 37,500 shares and sold $125,186 worth of shares (14,625 units at $8.56), increasing direct ownership by 6% to 387,225 units (SEC Form 4)

    4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

    2/10/26 4:49:28 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Finance & Corp Controller Sangiovanni Timothy J. sold $27,548 worth of shares (3,000 units at $9.18), decreasing direct ownership by 9% to 29,590 units (SEC Form 4)

    4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

    2/4/26 4:27:22 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CCO Schafer Joshua sold $96,500 worth of shares (10,500 units at $9.19), decreasing direct ownership by 14% to 62,278 units (SEC Form 4)

    4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

    2/4/26 4:27:11 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Favorito Tamara A bought $24,718 worth of shares (3,175 units at $7.79), increasing direct ownership by 442% to 3,894 units (SEC Form 4)

    4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

    9/16/25 4:15:37 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Shih Alvin bought $157,800 worth of shares (20,000 units at $7.89) (SEC Form 4)

    4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

    9/15/25 4:07:29 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bode John B bought $45,825 worth of shares (5,000 units at $9.16), increasing direct ownership by 12% to 45,000 units (SEC Form 4)

    4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

    8/20/25 4:38:00 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVRA
    Leadership Updates

    Live Leadership Updates

    View All

    Zevra Therapeutics Appoints Justin Renz as Chief Financial Officer

    CELEBRATION, Fla., March 05, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the appointment of Justin Renz as Chief Financial Officer, effective March 9, 2026. Mr. Renz brings more than 25 years of financial leadership experience in the biopharmaceutical industry, including extensive expertise in capital markets, strategic transactions, and commercial-stage operations. "Justin is a highly accomplished financial executive with a strong track record of driving growth and creating shareholder value across multiple biopharmaceutical organizat

    3/5/26 7:30:00 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Transpire Bio Strengthens its Leadership Team with Appointment of LaDuane Clifton as Chief Financial Officer

    SUNRISE, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announced the appointment of R. LaDuane Clifton as Chief Financial Officer (CFO). "As Transpire Bio continues to progress from a clinical-stage to commercial-stage biopharmaceutical company, we are aligning our leadership structure to support the next phase of our growth," said Dr. Xian-Ming Zeng, Chief Executive Officer of Transpire Bio. "We are thrilled to welcome Mr. Clifton as Chief Financial Officer. He brings extensive public company, global finance, and operations leadership

    2/24/26 3:42:26 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD

    CELEBRATION, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the appointment of Alicia Secor to the Company's Board of Directors (Board). The Company also announced the retirement of director Wendy Dixon, PhD, effective today. "We are pleased to welcome Alicia to our Board at this important juncture, as her expertise will support our continued execution of strategy and our commitment to delivering durable, sustained value for shareholders," said Tamara A. Favorito, Zevra's Chair of the Board. "We sincerely appreciate Wendy's

    12/2/25 7:30:00 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Zevra Therapeutics Inc.

    SC 13G - ZEVRA THERAPEUTICS, INC. (0001434647) (Subject)

    11/14/24 1:00:16 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zevra Therapeutics Inc.

    SC 13G/A - ZEVRA THERAPEUTICS, INC. (0001434647) (Subject)

    11/12/24 5:59:21 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zevra Therapeutics Inc.

    SC 13G/A - ZEVRA THERAPEUTICS, INC. (0001434647) (Subject)

    11/4/24 2:15:20 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVRA
    Financials

    Live finance-specific insights

    View All

    Zevra Reports Fourth Quarter and Full Year 2025 Financial Results

    Q4 net revenue of $34.1 million, representing 31% growth quarter-over-quarter FY 2025 net revenue of $106.5 million, driven by growth in MIPLYFFA® net revenue to $87.4 million 2025 EPS of $1.40 basic and $1.35 diluted  Company to host conference call and webcast TODAY, March 9, 2026, at 4:30 p.m. ET BOSTON, March 09, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today reported its financial results for the fourth quarter and full year ended December 31, 2025. "MIPLYFFA is making a meaningful difference for patients with Niemann-Pick disease type C, a

    3/9/26 4:05:00 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call

    CELEBRATION, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it will report corporate and financial results for the fourth quarter and full year 2025 on Monday, March 9, 2026, via a news release after the market close, and will host a conference call/audio webcast at 4:30 p.m. ET that day. A link to the audio webcast will be accessible on the "Events & Presentations" page in the Investor Relations section of Zevra's website at investors.zevra.com. To join via telephone, please use the following dial-in information: (800)

    3/2/26 7:30:00 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zevra Reports Third Quarter 2025 Financial Results and Corporate Update

    2025 EPS of $(0.01) Q3 2025 net revenue of $26.1 million, driven by MIPLYFFA® net revenue of $22.4 million Company to host conference call and webcast TODAY, November 5, 2025, at 4:30 p.m. ET CELEBRATION, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today reported its financial results for the three and nine months ended September 30, 2025. "Zevra is well-positioned for continued growth, driven by the strong performance of MIPLYFFA and the meaningful impact we are delivering to patients with Niemann-Pick disease type C," said Neil F.

    11/5/25 4:05:00 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care